{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:30:01Z","timestamp":1789039801079,"version":"build-2803163510"},"reference-count":162,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Asthma and nasal polyposis often coexist and are frequently intertwined by tight pathogenic links, mainly consisting of the cellular and molecular pathways underpinning type 2 airway inflammation. The latter is characterized by a structural and functional impairment of the epithelial barrier, associated with the eosinophilic infiltration of both the lower and upper airways, which can be driven by either allergic or non-allergic mechanisms. Type 2 inflammatory changes are predominantly due to the biological actions exerted by interleukins 4 (IL-4), 13 (IL-13), and 5 (IL-5), produced by T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). In addition to the above cytokines, other proinflammatory mediators involved in the pathobiology of asthma and nasal polyposis include prostaglandin D2 and cysteinyl leukotrienes. Within this context of \u2018united airway diseases\u2019, nasal polyposis encompasses several nosological entities such as chronic rhinosinusitis with nasal polyps (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). Because of the common pathogenic origins of asthma and nasal polyposis, it is not surprising that the more severe forms of both these disorders can be successfully treated by the same biologic drugs, targeting many molecular components (IgE, IL-5 and its receptor, IL-4\/IL-13 receptors) of the type 2 inflammatory trait.<\/jats:p>","DOI":"10.3390\/jcm12103371","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T01:57:51Z","timestamp":1683683871000},"page":"3371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-7367","authenticated-orcid":false,"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-1686","authenticated-orcid":false,"given":"Angelantonio","family":"Maglio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Tinello","sequence":"additional","affiliation":[{"name":"Pediatrics Unit, Provincial Outpatient Center of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":false,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-399X","authenticated-orcid":false,"given":"Nicola","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Terracciano","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-3037","authenticated-orcid":false,"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Matucci, A., Bormioli, S., Nencini, F., Chiccoli, F., Vivarelli, E., Maggi, E., and Vultaggio, A. (2021). Asthma and chronic rhinosinusitis: How similar are they in pathogenesis and treatment responses?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073340"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hakansson, K., Bachert, C., Konge, L., Thomsen, S.F., Pedersen, A.E., Poulsen, S.S., Martin-Bertelsen, T., Winther, O., Backer, V., and von Buchwald, C. (2015). Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: The united airways concept further supported. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127228"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otc.2022.09.001","article-title":"Unified airway disease: A contemporary review and introduction","volume":"56","author":"Fokkens","year":"2023","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_7","first-page":"45","article-title":"Nasal polyps in patients with asthma: Prevalence, impact and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"ref_8","first-page":"P3448","article-title":"Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study)","volume":"42","author":"Castillo","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.anai.2018.02.005","article-title":"Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset","volume":"120","author":"Won","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-101320-030339","article-title":"Emerging paradigms in type 2 immunity","volume":"40","author":"Hammad","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaip.2019.11.024","article-title":"Eosinophilic asthma","volume":"8","author":"Nelson","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jaci.2021.03.016","article-title":"What is the contribution of IgE to nasal polyposis?","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1067\/mai.2002.122458","article-title":"Chronic sinusitis in severe asthma is related to sputum eosinophilia","volume":"109","author":"Grootendorst","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cea.13772","article-title":"Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatics","volume":"51","author":"Flora","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2022.2074402","article-title":"S. aureus and IgE-mediated diseases: Pilot or copilot? A narrative review","volume":"18","author":"Calabrese","year":"2022","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.iac.2012.11.002","article-title":"Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease","volume":"33","author":"Mullol","year":"2013","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease\u2014New prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2022.09.001","article-title":"The understanding of asthma pathogenesis in the era of precision medicine","volume":"72","author":"Hizawa","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1113100","DOI":"10.3389\/fphys.2023.1113100","article-title":"Airway remodeling heterogeneity in asthma and its relationship to disease outcomes","volume":"14","author":"Hsieh","year":"2023","journal-title":"Front. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2020.01.013","article-title":"Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis","volume":"124","author":"Staudacher","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2020.08.001","article-title":"Group 2 innate lymphoid cells in nasal polyposis","volume":"126","author":"Stevens","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cea.12472","article-title":"Pathogenesis of nasal polyposis","volume":"45","author":"Huise","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.otc.2022.09.012","article-title":"Unified airway disease: Medical management","volume":"56","author":"Shamil","year":"2023","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.alit.2022.06.007","article-title":"Distinct subsets of innate lymphoid cells in nasal polyp","volume":"72","author":"Kim","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-immunol-110119-091711","article-title":"Group 2 innate lymphoid cells: Team players in regulating asthma","volume":"39","author":"Gogoi","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/1744666X.2020.1860755","article-title":"The emerging role of type 2 inflammation in asthma","volume":"17","author":"Matucci","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Poto, R., Criscuolo, G., Marone, G., Brightling, C.E., and Varricchi, G. (2022). Human lung mast cells: Therapeutic implications in asthma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214466"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Iype, J., and Fux, M. (2021). Basophils orchestrating eosinophils\u2019 chemotaxis and function in allergic inflammation. Cells, 10.","DOI":"10.3390\/cells10040895"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Vatrella, A., Maglio, A., Pelaia, C., Ciampo, L., Pelaia, G., and Vitale, C. (2022). Eosinophilic inflammation: An appealing target for pharmacologic treatments in severe asthma. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092181"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: Key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Calven, J., Ax, E., and Radinger, M. (2020). The airway epithelium\u2014A central player in asthma pathogenesis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238907"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lameire, S., and Hammad, H. (2023). Lung epithelial cells: Upstream targets in type 2-high asthma. Eur. J. Immunol., in press.","DOI":"10.1002\/eji.202250106"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100995","DOI":"10.1016\/j.mam.2021.100995","article-title":"Cellular and molecular mechanisms of allergic asthma","volume":"85","author":"Komlosi","year":"2022","journal-title":"Mol. Asp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision making: How does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2017.00214","article-title":"Interleukin-4 inhibits regulatory T cell differentiation through regulating CD103+ dendritic cells","volume":"8","author":"Tu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/imr.12555","article-title":"Mechanisms of immune regulation in allergic diseases: The role of regulatory T and B cells","volume":"278","author":"Palomares","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nri1181","article-title":"The regulation of immunoglobulin E class-switch recombination","volume":"9","author":"Geha","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","article-title":"The intriguing role of interleukin 13 in the pathophysiology of asthma","volume":"10","author":"Marone","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12967-020-02251-w","article-title":"Alternatively activated macrophages; a double-edged sword in allergic asthma","volume":"18","author":"Abdelaziz","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104252","DOI":"10.1016\/j.cellimm.2020.104252","article-title":"Sex differences in M2 polarization, chemokine and IL-4 receptors in monocytes and macrophages from asthmatics","volume":"360","author":"Lerner","year":"2021","journal-title":"Cell. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.5415\/apallergy.2020.10.e14","article-title":"Mechanisms of eosinophilic inflammation","volume":"10","author":"Nagata","year":"2020","journal-title":"Asia Pac. Allergy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.otc.2022.09.005","article-title":"Unified airway disease: Examining prevalence and treatment of upper airway eosinophilic disease with comorbid asthma","volume":"56","author":"Mehta","year":"2023","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2016.02.035","article-title":"Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma","volume":"139","author":"Sweerus","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2019.04.027","article-title":"Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis","volume":"144","author":"Steelant","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e24333","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/15548627.2015.1056967","article-title":"IL-13 activates autophagy to regulate secretion in airway epithelial cells","volume":"12","author":"Dickinson","year":"2016","journal-title":"Autophagy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/all.13424","article-title":"Role of IL-13R\u03b12 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa","volume":"73","author":"Liu","year":"2018","journal-title":"Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1172\/JCI84910","article-title":"Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma","volume":"126","author":"Bonser","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ACI.0000000000000877","article-title":"Exhaled nitric oxide in asthma: From diagnosis to management","volume":"23","author":"Guida","year":"2023","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11882-013-0373-9","article-title":"Role of interleukin-13 in asthma","volume":"13","author":"Corren","year":"2013","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor-\u03b21","volume":"194","author":"Lee","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1183\/09031936.00068712","article-title":"Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-\u03b21 in airway fibroblasts in asthma","volume":"43","author":"Firszt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201207-1292OC","article-title":"Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression","volume":"187","author":"Takabayashi","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Stanziola, A.A., Calabrese, C., Terracciano, R., Longhini, F., and Vatrella, A. (2022). Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051064"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.rmed.2007.01.026","article-title":"Apoptotic eosinophils in sputum from asthmatic patients correlate negatively with levels of IL-5 and eotaxin","volume":"101","author":"Xu","year":"2007","journal-title":"Respir. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","article-title":"Targeting eosinophils in allergy, inflammation and beyond","volume":"12","author":"Fulkerson","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.iac.2018.06.003","article-title":"Airway eosinophilopoietic and autoimmune mechanisms of eosinophilia in severe asthma","volume":"38","author":"Bhalla","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fmed.2017.00075","article-title":"Eosinophil activation status in separate compartments and association with asthma","volume":"4","author":"Johansson","year":"2017","journal-title":"Front. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.4049\/jimmunol.164.4.2142","article-title":"The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity","volume":"164","author":"Mould","year":"2000","journal-title":"J. Immunol."},{"key":"ref_75","first-page":"547","article-title":"Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma","volume":"51","author":"Vatrella","year":"1996","journal-title":"Allergy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1165\/ajrcmb.15.3.8810646","article-title":"Transforming growth factor \u03b21 (TGF-\u03b21) gene expression by eosinophils in asthmatic airway inflammation","volume":"15","author":"Ohno","year":"1996","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/all.13997","article-title":"Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma","volume":"75","author":"Choi","year":"2020","journal-title":"Allergy"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Van Hulst, G., Bureau, F., and Desmet, C.J. (2021). Eosinophils as drivers of severe eosinophilic asthma: Endotypes or plasticity?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810150"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000072140","article-title":"Association of interleukin-5 and eotaxin with acute exacerbation of asthma","volume":"131","author":"Park","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/JCD.S13588","article-title":"Regulation of spontaneous eosinophil apoptosis\u2014A neglected area of importance","volume":"7","author":"Ilmarinen","year":"2014","journal-title":"J. Cell Death"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0091-6749(97)80019-X","article-title":"IL-5 synthesis is upregulated in human nasal polyp tissue","volume":"99","author":"Bachert","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/0194599816637856","article-title":"Clinical examination of tissue eosinophilia in patients with chronic rhinosinusitis and nasal polyposis","volume":"155","author":"Gitomer","year":"2016","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.waojou.2019.100052","article-title":"Concordant systemic and local eosinophilia relates to poorer disease control in patients with nasal polyps","volume":"12","author":"Wang","year":"2019","journal-title":"World Allergy Organ. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int. Forum Allergy"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bakakos, A., Schleich, F., and Bakakos, P. (2022). Biological therapy of severe asthma and nasal polyps. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060976"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1753466618810192","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of asthma: More than a decade of real life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S130743","article-title":"Targeted therapy in severe asthma today: Focus on immunoglobulin E","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1389450116666141219122157","article-title":"Anti-IgE therapy with omalizumab for severe asthma: Current concepts and potential developments","volume":"16","author":"Pelaia","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/JAA.S246902","article-title":"FENOMA study: Achieving full control in patients with severe allergic asthma","volume":"13","author":"Cabrejos","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pupt.2018.11.002","article-title":"Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-year single centre observational study","volume":"54","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/02770903.2011.561512","article-title":"Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics","volume":"48","author":"Pace","year":"2011","journal-title":"J. Asthma"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4168\/aair.2017.9.4.368","article-title":"Real life efficacy of omalizumab after 9 years of follow-up","volume":"9","author":"Menzella","year":"2017","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study","volume":"130","author":"Fiorino","year":"2017","journal-title":"Respir. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.2147\/DDDT.S226575","article-title":"Chronic rhinosinusitis with nasal polyps: Targeting IgE with anti-IgE omalizumab therapy","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: A real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: From the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Design Dev. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITY-A and beyond: Mepolizumab for treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: Initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101899","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Maglio, A., Vitale, C., Pellegrino, S., Calabrese, C., D\u2019Amato, M., Molino, A., Pelaia, C., Triggiani, M., Pelaia, G., and Stellato, C. (2021). Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111550"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Maglio, A., Vitale, C., Pelaia, C., D\u2019Amato, M., Ciampo, L., Sferra, E., Molino, A., Pelaia, G., and Vatrella, A. (2023). Severe asthma remissions induced by biologics targeting IL-5\/IL-5R: Results from a multicenter real-life study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032455"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: A 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/TCRM.S111862","article-title":"Role of biologics in severe eosinophilic asthma: Focus on reslizumab","volume":"12","author":"Pelaia","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2017.00242","article-title":"Reslizumab and eosinophilic asthma: One step closer to precision medicine?","volume":"8","author":"Varricchi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effects of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.chest.2020.11.060","article-title":"Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice","volume":"159","author":"Wechsler","year":"2021","journal-title":"Chest"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: Design, development and potential place in therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomized, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate persistent asthma (BISE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): A multicentre, open-label, single-arm study","volume":"10","author":"Gurnell","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN severe uncontrolled Asthmatic patients Key features when receiving Benralizumab in a real-life setting: The observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir. Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Crimi, C., Nolasco, S., Carpagnano, G.E., Brancaccio, R., Buonamico, E., Campisi, R., Gagliani, C., Patella, V., and Pelaia, G. (2021). Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: A real-life experience from Southern Italy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121822"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-life rapidity of benralizumab effects in patients with severe allergic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"BioMed Pharmacother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cea.14026","article-title":"Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis","volume":"52","author":"Crimi","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): A randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: A real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2058738420950851","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14712598.2017.1387245","article-title":"Dupilumab for the treatment of asthma","volume":"17","author":"Pelaia","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with dupilumab in severe asthma: One-year data from an Italian Named Patient Program","volume":"14","author":"Campisi","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/JAA.S328988","article-title":"Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis","volume":"14","author":"Pelaia","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1121237","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_162","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:27Z","timestamp":1760124747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":162,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103371"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103371","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}